Skip to main content
Terug
AGYTF logo

Allergy Therapeutics plc

Datakwaliteit: 100%
Overbought
AGYTF
OTC Healthcare Drug Manufacturers - Specialty & Generic
€ 0,11
€ 0,00 (0,00%)
Marktkapitalisatie: 504,57M
Dagbereik
€ 0,11 € 0,11
52-Weeksbereik
€ 0,05 € 0,11
Volume
15.000
50D / 200D Gem.
€ 0,11 / € 0,10
Vorige Slotkoers
€ 0,11

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -9,2 0,4
P/B 2,9
ROE % 3,8
Net Margin % -72,9 3,9
Rev Growth 5Y % -2,7 10,0
D/E 0,2

Belangrijkste Punten

Revenue declined -2,71% annually over 5 years
Negative free cash flow of -43,90M
PEG of 0,25 suggests growth is underpriced
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 39,60%
Capital efficient — spends only 5,93% of revenue on capex

Groei

Revenue Growth (5Y)
-2,71%
Revenue (1Y)36,89%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
N/A
ROIC-98,76%
Net Margin-72,91%
Op. Margin-37,27%

Veiligheid

Debt / Equity
N/A
Current Ratio0,93
Interest Coverage-4,21

Waardering

P/E Ratio
-9,16
P/B RatioN/A
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 36,89% Revenue Growth (3Y) 12,61%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -2,71% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 75,56M Net Income (TTM) -55,09M
ROE N/A ROA -81,57%
Gross Margin 45,65% Operating Margin -37,27%
Net Margin -72,91% Free Cash Flow (TTM) -43,90M
ROIC -98,76% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0,93
Interest Coverage -4,21 Dividend Yield 0,00%
Valuation
P/E Ratio -9,16 P/B Ratio N/A
P/S Ratio 6,68 PEG Ratio 0,25
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 504,57M Enterprise Value 547,10M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 75,56M 55,20M 59,59M 72,77M 84,33M
Net Income -55,09M -40,22M -43,07M -13,78M 2,89M
EPS (Diluted) -0,01 -0,01 -0,04 -0,01 0,00
Gross Profit 34,50M 29,74M 33,25M 49,51M 62,23M
Operating Income -28,16M -35,26M -39,65M -12,25M 4,03M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 67,54M 64,83M 66,77M 73,58M 88,09M
Total Liabilities 131,43M 61,12M 64,70M 35,18M 39,55M
Shareholders' Equity -38,70M 3,71M 2,07M 37,77M 48,54M
Total Debt 60,09M 30,99M 35,99M 10,53M 11,17M
Cash & Equivalents 17,56M 12,72M 14,65M 20,52M 40,27M
Current Assets 34,68M 33,48M 33,53M 42,39M 57,86M
Current Liabilities 37,33M 20,55M 18,57M 17,80M 18,23M